Role of cytokines and chemokines in non-alcoholic fatty liver disease

被引:271
作者
Braunersreuther, Vincent [1 ]
Viviani, Giorgio Luciano [2 ]
Mach, Francois [1 ]
Montecucco, Fabrizio [1 ]
机构
[1] Univ Hosp Geneva, Div Cardiol, Fdn Med Res, Fac Med, CH-1211 Geneva, Switzerland
[2] Univ Genoa, Dept Internal Med, Adult Diabet Ctr, I-16143 Genoa, Italy
关键词
Inflammation; Non-alcoholic fatty liver disease; Cytokine; Chemokine; TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHOLINE-DEFICIENT DIET; GROWTH-FACTOR-BETA; INDUCED INSULIN-RESISTANCE; HEPATIC STELLATE CELLS; FACTOR-ALPHA; TNF-ALPHA; GENE-EXPRESSION; ADIPOSE-TISSUE;
D O I
10.3748/wjg.v18.i8.727
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions (ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are characterized by an increased fat content within the liver. The accumulation/deposition of fat within the liver is essential for diagnosis of NAFLD and might be associated with alterations in the hepatic and systemic inflammatory state. Although it is still unclear if each histological entity represents a different disease or rather steps of the same disease, inflammatory processes in NAFLD might influence its pathophysiology and prognosis. In particular, non-alcoholic steatohepatitis (the most inflamed condition in NAFLDs, which more frequently evolves towards chronic and serious liver diseases) is characterized by a marked activation of inflammatory cells and the upregulation of several soluble inflammatory mediators. Among several mediators, cytokines and chemokines might play a pivotal active role in NAFLD and are considered as potential therapeutic targets. In this review, we will update evidence from both basic research and clinical studies on the potential role of cytokines and chemokines in the pathophysiology of NAFLD. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:727 / 735
页数:9
相关论文
共 109 条
[1]   Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis [J].
Abiru, S ;
Migita, K ;
Maeda, Y ;
Daikoku, M ;
Ito, M ;
Ohata, K ;
Nagaoka, S ;
Matsumoto, T ;
Takil, Y ;
Kusumoto, K ;
Nakamura, M ;
Komori, A ;
Yano, K ;
Yatsuhashi, H ;
Eguchi, K ;
Ishibashi, H .
LIVER INTERNATIONAL, 2006, 26 (01) :39-45
[2]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[3]  
ANDERSEN T, 1984, INT J OBESITY, V8, P107
[4]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[5]   Diagnosing Steatohepatitis and Predicting Liver-Related Mortality in Patients with NAFLD: Two Distinct Concepts [J].
Angulo, Paul .
HEPATOLOGY, 2011, 53 (06) :1792-1794
[6]   INCREASED TRANSFORMING GROWTH FACTOR-BETA-1 GENE-EXPRESSION IN HUMAN LIVER-DISEASE [J].
ANNONI, G ;
WEINER, FR ;
ZERN, MA .
JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) :259-264
[7]  
Bahcecioglu IH, 2005, HEPATO-GASTROENTEROL, V52, P1549
[8]   Effects of etanercept in patients with the metabolic syndrome [J].
Bernstein, LE ;
Berry, J ;
Kim, S ;
Canavan, B ;
Grinspoon, SK .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (08) :902-908
[9]   Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice [J].
Berres, Marie-Luise ;
Koenen, Rory R. ;
Rueland, Anna ;
Zaldivar, Mirko Moreno ;
Heinrichs, Daniel ;
Sahin, Hacer ;
Schmitz, Petra ;
Streetz, Konrad L. ;
Berg, Thomas ;
Gassler, Nikolaus ;
Weiskirchen, Ralf ;
Proudfoot, Amanda ;
Weber, Christian ;
Trautwein, Christian ;
Wasmuth, Hermann E. .
JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (11) :4129-4140
[10]   Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients [J].
Bertola, Adeline ;
Bonnafous, Stephanie ;
Anty, Rodolphe ;
Patouraux, Stephanie ;
Saint-Paul, Marie-Christine ;
Iannelli, Antonio ;
Gugenheim, Jean ;
Barr, Jonathan ;
Mato, Jose M. ;
Le Marchand-Brustel, Yannick ;
Tran, Albert ;
Gual, Philippe .
PLOS ONE, 2010, 5 (10)